By Robert C. Doebele, MD, PhD Posted: December 11, 2019 Dr. Robert C. Doebele Early in the drug development of targeted therapies, specific oncogene mutations were often associated with a […] Read more
PROVIDER RESOURCES
MARIPOSA OS Data Confirms Improved Efficacy for Amivantamab Plus Lazertinib in the First Line for EGFR-mutated NSCLC
INDUSTRY SUPPORTED
COCOON’s Prophylactic Regimen Resulted in Decreased Incidence and Severity of Dermatologic-related Adverse Events